Cargando…
The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort
Introduction A major barrier for successful therapeutic approaches for COVID-19 is the inability to diagnose COVID-19 during the viral replication stage, when drugs with potential antiviral activity could demonstrate efficacy and preclude progression to more severe stages. Reasons that hamper an ear...
Autores principales: | Cadegiani, Flavio A, Zimerman, Ricardo A, Campello de Souza, Bruno, McCoy, John, Pereira e Costa, Rute Alves, Gustavo Wambier, Carlos, Goren, Andy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793341/ https://www.ncbi.nlm.nih.gov/pubmed/33437562 http://dx.doi.org/10.7759/cureus.12565 |
Ejemplares similares
-
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
por: Cadegiani, Flavio A, et al.
Publicado: (2021) -
Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021) -
Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants
por: Zimerman, Ricardo A, et al.
Publicado: (2021) -
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021) -
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
por: Cadegiani, F.A., et al.
Publicado: (2021)